ZFTA-KLHL20 Programme
Cancers with ZFTA fusions (e.g., ependymoma)
Discovery/Pre-clinicalActive
Key Facts
Indication
Cancers with ZFTA fusions (e.g., ependymoma)
Phase
Discovery/Pre-clinical
Status
Active
Company
About Beactica Therapeutics
Beactica Therapeutics is an emerging, private biotech transitioning from a service-oriented fragment-based lead generation (FBLG) company to a therapeutics developer with a proprietary pipeline. Its core asset is the Eclipsor™ platform, which integrates allosteric modulation and targeted protein degradation to create novel therapeutics. The company has a validated track record through prior partnerships, has received FDA Orphan Drug Designation for its lead asset BEA-17 in glioblastoma, and is positioned as a 'TPD Company to Watch' with ambitions to become a clinical-stage precision oncology company.
View full company profile